stockvaper
5年前
Meridian Bioscience Says New Covid-19 Sample Prep Eliminates Dependence on Reagents
BY Dow Jones & Company, Inc.
04/27/2020
Meridian Bioscience, Inc. (VIVO) said Monday it was launching "a novel enzyme master mix that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular assay."
The company said by eliminating the step, total assay cost is lower and processing times for Covid-19 samples can be cut by as much as 30 minutes a test.
"We have already shared this new master mix with nearly 20 early access laboratories around the globe, and their feedback has been quite positive," said Todd Howren, vice president of Global Sales at Meridian.
stockvaper
5年前
Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak
"Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans. The outbreak started on the Chinese city of Wuhan, 56 people have already died and more than 2,000 confirmed infected. This new virus has already spread to other parts of mainland China and several other countries and health authorities around the world are taking action to prevent a global epidemic.
The World Health Organization (WHO) has provided interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with 2019-nCoV. Sequence information from the 2019-nCoV has recently been made available and diagnostic companies and laboratories in China have turned to Meridian’s Lyo-Ready 1-Step RT-qPCR Mix to develop fast and accurate screening assays. Meridian’s manufacturing team is working diligently to meet the supply of critical reagents for the detection of Coronavirus and fast response to the outbreak.
Dr. Liang Zhang, General Manager for Meridian in China, commented, “The advantage of the Meridian Lyo-Ready 1-Step RT-qPCR Mix is that the assay can be set up and freeze-dried, so that they are highly stable, just requiring the patient sample to be added and the assay run. This means that patients can be screened very quickly to help stop the spread of this virus. We are pleased to have a reagent that works so well and makes economic sense for Coronavirus diagnostics during these times of great urgency.”
Dr. Steve Hawkins, Product Marketing Manager added. “Over the last few days we have seen significant demand for our Lyo-Ready One-Step RT-qPCR Mix. This ready-to-use, lyophilization-friendly mix is designed to improve the accuracy of assays, increase operational efficiencies and reduce their overall costs, making screening fast and affordable, upholding our commit to bringing innovation and quality products to the IVD community, especially in times of need.”
https://investor.meridianbioscience.com/news-releases/news-release-details/meridian-bioscience-lyo-ready-1-step-rt-qpcr-mix-used
stockvaper
5年前
Meridian Bioscience to Acquire Exalenz Bioscience
02/19/2020
Meridian Bioscience ( VIVO ) said Wednesday that it has agreed to acquire Exalenz Bioscience for 6.10 Israeli new shekels ($1.78) per share in cash, representing a total equity value of about 169 million shekels ($49.4 million).
Through the acquisition, Exalenz's flagship urea breath test platform, BreathID Breath Test Systems, for the detection of Helicobacter pylori, will be transferred to Meridian.
The agreement has received unanimous approval from the boards of both companies.
Meridian will fund the transaction with cash on hand and debt available under its credit facility, which is being expanded to $160 million.
The transaction, subject to Exalenz shareholder approval and other customary closing conditions, is expected to be completed in Q2.
In 2019 Exalenz reported about $14 million in revenue, representing a five-year compound annual growth rate of about 32%, and gross profit margin of around 50%. Meridian said it would discuss the fiscal year 2020 financial impact of the deal during its Q2 earnings call.
https://eresearch.fidelity.com/eresearch/evaluate/news/basicNewsStory.jhtml?symbols=VIVO&storyid=202002190955MIDNIGHTUSEQUITY_A2098234&provider=MIDNIGHT&product=USEQUITY
stockvaper
5年前
Newbie here. Just bought some VIVO today. GLTA
Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak
January 27, 2020 at 9:17 AM EST
CINCINNATI, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans. The outbreak started on the Chinese city of Wuhan, 56 people have already died and more than 2,000 confirmed infected. This new virus has already spread to other parts of mainland China and several other countries and health authorities around the world are taking action to prevent a global epidemic.
The World Health Organization (WHO) has provided interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with 2019-nCoV. Sequence information from the 2019-nCoV has recently been made available and diagnostic companies and laboratories in China have turned to Meridian’s Lyo-Ready 1-Step RT-qPCR Mix to develop fast and accurate screening assays. Meridian’s manufacturing team is working diligently to meet the supply of critical reagents for the detection of Coronavirus and fast response to the outbreak.
Dr. Liang Zhang, General Manager for Meridian in China, commented, “The advantage of the Meridian Lyo-Ready 1-Step RT-qPCR Mix is that the assay can be set up and freeze-dried, so that they are highly stable, just requiring the patient sample to be added and the assay run. This means that patients can be screened very quickly to help stop the spread of this virus. We are pleased to have a reagent that works so well and makes economic sense for Coronavirus diagnostics during these times of great urgency.”
Dr. Steve Hawkins, Product Marketing Manager added. “Over the last few days we have seen significant demand for our Lyo-Ready One-Step RT-qPCR Mix. This ready-to-use, lyophilization-friendly mix is designed to improve the accuracy of assays, increase operational efficiencies and reduce their overall costs, making screening fast and affordable, upholding our commit to bringing innovation and quality products to the IVD community, especially in times of need.”
For complete information, please visit meridianlifescience.com/molecular-dx-reagents.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
Contact:
Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com
https://investor.meridianbioscience.com/news-releases/news-release-details/meridian-bioscience-lyo-ready-1-step-rt-qpcr-mix-used
Brando1975
7年前
Vivo mentioned in Seeking Alpha article.
When You're Knocked Off The Horse…Get Back On! The Mantra Of A Biotech Investor…A Look Back On The Last 12 Months
Oct. 18, 2017 1:36 AM
When You're Knocked Off the Horse! Get Back On!
The Mantra of a Biotech Investor...A Look Back on the Last 12 Months
10-18-2017
I realize it's been nearly six months since my last update. My absence has not been due to lack of activity in my biotech picks. It's been 1 year since my first "Knocked Off the Horse" article. I'm taking the one-year anniversary as an opportunity to see how the last year treated my stable. The performance of a couple of my thoroughbreds had me cashing in at the ticket window and a couple of nags needed to be sent out to pasture. I'll provide a brief update on the last few months and do my best at looking forward.
ZIVO, Zivo Bioscience - Added on 2.2.17, pps on 2.2.2016 - .11, pps October 2017 - $.07 ZIVO is in my "not followed" category. These are companies with interesting stories or science but essentially no one has heard of them. I'm still hanging onto ZIVO, she's a bit boring and still doesn't trade much, but they continue to progress with their algae technology. I wouldn't bet on this to win, but she might come in with a place or show for me. She stays in the stable for now.
PKTX, ProtoKinetix - October 2016 pps - .07, October 2017 pps - .07. Don't be fooled by the price being the same in now as it was in October 2016. This company has made far greater strides than what I had even imagined. The company began its first human trials this year and the stock got as high as $.15 on the news. I would anticipate data from these trials to begin coming out early in 2018. The trials that are currently underway are for Diabetes, that in and of itself is enough for me to own the stock, but the company put press out on 10.17.2017 and informed us that they will also be using their molecule for Kidney Ischemia, Normothermic Liver Perfusion, Retinal Cell Replacement and Monocional antibody production. This company is no one trick pony! The stock doesn't get the attention it should, this is in large part due to the fact it is trading at $.07, many biotech investors don't take a penny stock too seriously. A little due diligence shows that this company was resurrected from the dead by current management and now has an entirely clean cap table with no debt whatsoever and as evidenced by the recent press, they're really getting things done. It's not often I get this fired up about a penny stock biotech, but PKTX is a penny stock in price only. The cap table and technology are deserving of a market cap far greater than what the market is currently giving it. Once they begin to release study data the market will realize this is Secretariat and not some also ran. I'm loading up on this one while she's still priced like a longshot.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
ClayTrader
5年前
crudeoil24
5年前
lambchops
7年前
